CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition.
On May 5, 2017, CytomX Therapeutics, Inc., a Delaware corporation
(the Company) issued a press release announcing its unaudited
financial results for the three months ended March 31, 2017. A
copy of the press release is furnished herewith as Exhibit 99.1.
The information in this Item 2.02 of this Form 8-K, including
Exhibit 99.1 attached hereto, is being furnished and shall not be
deemed filed for purposes of Section 18 of the Securities and
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act of 1933, as amended. The information contained in
this Item 2.02 and in the accompanying Exhibit 99.1 shall not be
incorporated by reference into any filing with the Securities and
Exchange Commission made by the Company, whether made before or
after the date hereof, regardless of any general incorporation
language in such filing.
|
Item 9.01 |
Financial Statements and Exhibits. |
Reference is made to the Exhibit Index attached hereto
About CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX)
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program. CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Recent Trading Information
CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) closed its last trading session down -0.24 at 14.64 with 307,239 shares trading hands.
